Abstracts tagged "rheumatoid arthritis (RA) and sarcopenia"

Abstract Number: 2470 • 2018 ACR/ARHP Annual Meeting
The Impact of Frailty on Changes in Physical Function Among Adults with Rheumatoid Arthritis
James Andrews¹, Laura Trupin², Catherine Hough¹, Edward H. Yelin³ and Patricia Katz², ¹Medicine, University of Washington, Seattle, WA, ²University of California San Francisco, San Francisco, CA, ³Medicine/Rheumatology, University of California San Francisco, San Francisco, CA
Background/Purpose: Frailty is a state of excess vulnerability to stressors and is associated with increased risk of poor health outcomes including physical disability. Frailty and…
Abstract Number: 460 • 2015 ACR/ARHP Annual Meeting
Changes in Body Composition and Metabolic Profile during Treatment with Tocilizumab in Patients with Rheumatoid Arthritis
Anne Tournadre¹, Bruno Pereira², Frederic Dutheil³, Vincent Sapin⁴, Charlotte Giraud⁵, Sandrine Malochet-Guinamand⁶, Thomas Frayssac⁷, Sylvain Mathieu⁵, Jean-Jacques Dubost⁸ and Martin Soubrier⁸, ¹Rheumatology, UNH-UMR 1019 INRA University of Auvergne and Rheumatology department CHU Clermont-Ferrand, Clermont-Ferrand, France, ²Biostatistics unit (DRCI), CHU Clermont-Ferrand, Clermont-Ferrand, France, ³Preventive and Occupational Medicine, CHU G. Montpied Laboratory of Metabolic Adaptations to Exercise in Physiological and Pathological conditions EA3533, Clermont-Ferrand, France, ⁴Biochemistry and Molecular Biology Department CHU Clermont-Ferrand, Clermont Université, Université d'Auvergne, EA7281, Clermont-Ferrand, France, ⁵Rheumatology, Rheumatology department CHU Clermont-Ferrand, Clermont-Ferrand, France, ⁶Rheumatology Department,, Rheumatology department CHU Clermont-Ferrand, Clermont-Ferrand, France, ⁷Rheumatology, Rheumatology department CHU Clermont-Ferrand, Clermont-ferrand, France, ⁸Rheumatology department CHU Clermont-Ferrand, Clermont-Ferrand, France
Background/Purpose: Rheumatoid arthritis (RA) is characterized by increased cardiovascular risk and metabolic changes including cachectic obesity, insulin resistance, dyslipidemia. DMARDs decrease inflammation and could thus…
Abstract Number: 1427 • 2014 ACR/ARHP Annual Meeting
Low Prevalence of Sarcopenic Obesity in Rheumatoid Arthritis Patients with Moderate Clinical Activity
Nina Tello-Winniczuk¹, David Vega-Morales², Mario Garza-Elizondo¹, Dionicio Galarza-Delgado¹, Jorge Esquivel-Valerio¹, Octavio Ilizaliturri-Guerra³ and Jorge Rodriguez-Olivo⁴, ¹Departamento de Medicina Interna del Hospital Universitario “Dr. José Eleuterio González”, Universidad Autónoma de Nuevo León, Servicio de Reumatología, Departamento de Medicina Interna del Hospital Universitario “Dr. José Eleuterio González”, Universidad Autónoma de Nuevo León, Monterrey, Mexico, ²Rheumatology, Hospital Universitario UANL, Monterrey, Mexico, ³Departamento de Medicina Interna del Hospital Universitario “Dr. José Eleuterio González”, Universidad Autónoma de Nuevo León, Departamento de Medicina Interna del Hospital Universitario “Dr. José Eleuterio González”, Universidad Autónoma de Nuevo León, Monterrey, Mexico, ⁴Servicio de Reumatología, Departamento de Medicina Interna del Hospital Universitario “Dr. José Eleuterio González”, Universidad Autónoma de Nuevo León, Monterrey, Mexico
Background/Purpose .Rheumatoid arthritis is an inflammatory systemic disease that leads to body composition alterations. Objective: The aim of our study was to identify the prevalence…
Abstract Number: 1412 • 2014 ACR/ARHP Annual Meeting
Sarcopenia and Its Impact on Disability in Rheumatoid Arthritis, a Pilot Study
Meltem Alkan Melikoglu¹ and Kazim Senel², ¹Rheumatology, Ataturk University Faculty of Medicine, Erzurum, Turkey, ²Physical Medicine and Rehabilitation, Ataturk University Medical School, Erzurum, Turkey
Background/Purpose: Rheumatoid arthritis (RA) is associated with increased morbidity and mortality due to several metabolic deteriorations one of which is sarcopenia. The aim of this…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].